Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lerociclib + fulvestrant vs placebo + fulvestrant in HR+/HER2- advanced breast cancer
CTR20211931Phase 3Completed
- Sponsor
- G1 Therapeutics, Inc.
- Start
- Aug 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lerociclib in breast cancer, sponsored by G1 Therapeutics, Inc.. Started Aug 2021; status: completed.
02
Drugs
lerociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20211931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211931.